Silvan Tuerkcan
Stock Analyst at Citizens
(4.40)
# 358
Out of 5,182 analysts
177
Total ratings
47.7%
Success rate
21.69%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Downgrades: Market Perform | n/a | $52.95 | - | 16 | Mar 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $53.58 | +60.51% | 17 | Dec 23, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.41 | +126.76% | 5 | Nov 20, 2025 | |
| ENGN enGene Therapeutics | Maintains: Market Outperform | $18 → $21 | $7.61 | +175.95% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.87 | +51.41% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $6.64 | +20.48% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $12.18 | +80.62% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $0.99 | +508.64% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $9.67 | +251.60% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $28.90 | +55.71% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $44.17 | +13.20% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $7.23 | +107.47% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.47 | +72.91% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.68 | +92.31% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $14.71 | +715.77% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.17 | +683.41% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.30 | +73.91% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $13.09 | +60.43% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.20 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.71 | +61.73% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $77.32 | +262.13% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $12.23 | +47.18% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $52.95
Upside: -
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $53.58
Upside: +60.51%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.41
Upside: +126.76%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $7.61
Upside: +175.95%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.87
Upside: +51.41%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $6.64
Upside: +20.48%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $12.18
Upside: +80.62%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $0.99
Upside: +508.64%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $9.67
Upside: +251.60%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $28.90
Upside: +55.71%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.17
Upside: +13.20%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $7.23
Upside: +107.47%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.47
Upside: +72.91%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.68
Upside: +92.31%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $14.71
Upside: +715.77%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.17
Upside: +683.41%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.30
Upside: +73.91%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $13.09
Upside: +60.43%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.20
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.71
Upside: +61.73%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $77.32
Upside: +262.13%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $12.23
Upside: +47.18%